On this episode, we’re continuing our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We’ll hear from three researchers about their findings in prostate cancer trials reported at the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more

On this episode, we’re continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we’ll hear from several researchers about their findings in multiple myeloma. To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more

On this episode, we’re featuring authors discussing their impactful research presented at the 2022 ASH Annual Meeting and Exposition, focusing on findings in different subtypes of leukemia. To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more

This year’s San Antonio Breast Cancer Symposium took place last week. On this episode, we’re hearing from the authors of three high-impact studies that were presented at the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more

On this episode, we’re covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma. To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more

This week, we’re covering the FDA approval of pemigatinib for patients with myeloid or lymphoid neoplasms and an FGFR1 rearrangement. We’ll also discuss a long-term update from the STAMPEDE trial of radiotherapy in prostate cancer. Coverage of stories discussed this week on ascopost.com: FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 Rearrangement Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more

On this episode, we’re covering two studies that focused on the effects of mortgage discrimination on cancer care outcomes. The research—in colon and lung cancers—was presented during the 2022 ASCO Quality Care Symposium. To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more

On this episode, we’re highlighting speakers who presented data in skin cancers during the ESMO Congress 2022, including findings on tumor-infiltrating lymphocyte therapy in advanced melanoma, cemiplimab in cutaneous squamous cell carcinoma, and the association of circulating tumor DNA and disease recurrence in patients with later-stage melanoma. To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more

The 2022 ASCO Quality Care Symposium took place in Chicago over the weekend. On this episode, we’re featuring two speakers who presented data at the meeting: the first focuses on the effects of Medicaid expansion on cancer mortality rates, and the second describes efforts to improve prescribing practices for prophylactic colony stimulating factors in the treatment of neutropenia. To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more

On this episode, we’re highlighting speakers who presented data in breast cancer during the ESMO Congress 2022. The first speaker discusses patterns of genomic instability in metastatic breast cancer, and the second touches on oncofertility care for young patients with breast cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts ..read more